期刊文献+

重组人脑钠肽对心衰患者心室重构的影响及机制 被引量:3

The Effects and Mechanisms of rhBNP on the Vantricular Remodeling in Patients with Heart Failure
下载PDF
导出
摘要 目的研究重组人脑钠肽(rhBNP)对心衰患者心室重构的影响,并探讨其可能机制。方法 50例心衰患者随机分为rhBNP治疗组与对照组,每组25例,随访3个月,治疗前后分别测定LVEDD、EF及血清Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)、透明质酸(HA)和一氧化氮(NO)水平,并进行比较。结果 rhBNP治疗3个月后,血清PCⅢ、CⅣ和HA水平较治疗前显著降低[(100.8±10.5)μg/L vs(156.1±10.2)μg/L;(75.0±9.5)mg/L vs(105.7±11.0)mg/L;(85.2±9.3)mg/L vs(122.5±10.6)mg/L;P均<0.05],NO水平较治疗前显著增加[(92.20±9.6)μmol/L vs(76.82±10.1)μmol/L,P<0.05],对照组各指标无明显改变(P均>0.05)。结论 rhBNP治疗能改善心衰症状,减轻心室重构,其机制可能与降低血清中胶原水平、增加NO浓度有关。 Objective Toevaluate the effects and mechanisms of rhBNP on the vantricular remodeling in patients with heart failure. Methods Fifty patients with heart failure were selected and divided randomly into two groups: rhBNP treatment group and control group, each group had twenty-five patients. They were followed up for three months. The LVEDD and the concentrations of serum PC m, c IV, HA and NO Were measured before treatment and after three months treatment, then compared between two groups. Results After three months treatment, the concentrations of serum PC III, C IV and HA decreased in rhBNP treatment group ( 100.8 ± 10.5 ) μg/L vs ( 156.1 ± 10.2 ) μg/L; ( 75.0 ± 9.5 ) mg/L vs ( 105.7 ± 11.0 ) mg/L; ( 85.2 ±9.3 ) mg/L vs ( 122.5± 10.6 ) mg/ L; all P 〈 0.05 ; the levels of NO increased ( 92.20 ±9.6 ) μ mol/L vs ( 76.82 ± 10.1 ) μ mol/L, P 〈 0.05, while after three months followup, there were not significant differences of all observed indicators in control group ( all P 〉 0.05 ). Conclusion After rbBNP treatment, the serum levels of PC III, C IV and HA decreased and the levels of serum NO increased, which contributed to the improvement of the vantricular remodeling.
出处 《中国现代医生》 2011年第21期80-81,83,共3页 China Modern Doctor
关键词 脑钠肽 心衰 胶原 透明质酸 一氧化氮 BNP Heart failure Collagen Hyaluronic acid Natric oxide
  • 相关文献

参考文献1

二级参考文献15

  • 1Rabbani LE. Acute coronary syndromes-beyond myocyte necrosis. N Engl J Med,2001,345:1057-1059.
  • 2Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res,1999,31:487-498.
  • 3Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl,1999,230:132-142.
  • 4Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond),1998,95:519-529.
  • 5Maewal P, de Lemos JA. Natriuretic peptide hormone measurement in acute coronary syndromes. Heart Fail Rev,2003,8:365-368.
  • 6Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J,1998,135:21-28.
  • 7Berger R. Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation,2002,105:2392-2397.
  • 8Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol,2002, 89:463-465.
  • 9McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc,2003,4:S13-S19.
  • 10Kelly R, Struthers AD. Are natriuretic peptides clinically useful as markers of heart failure? Ann Clin Biochem,2001, 38:94-102.

共引文献65

同被引文献19

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部